Short term thinking investors might be. But the people who want in REGN already know this and have already bought the stock, its fairly common knowledge. REGN also is a very efficient, much smaller company than AMGN. Do they have the late stage pipeline AMGN does in other indications? Probably not. And AMGN already had a drug approved last week for heart disease patients. It could cause a similar pricing war effect, like with ABBV/GILD, but I don't know enough about the differences between each company's drug to say for sure.
People who were in the trial have been somewhat outspoken on the internet about how beneficial the vaccine was for them. Also, J&J and Glaxo are 2 of the largest shareholders, along with Polaris Ventures which is another large venture fund. So you have 2 huge pharma companies as the #2 and #3 holders of this company, they are going to want to see it through.
VICAL has much less cash than GNCA and has J&J and Glaxo as 2 of their top shareholders. They are further along as they are going to report PhII data this quarter. VICL from what I see started their trial in 2013?? GNCA finished their PH I/2a safety trials. I don't think VICL is even close to GNCA. Plus they have 80 million shares which is going to take a lot more buying to get the stock moving vs. 20 M for GNCA.
Comparing AMGN to BRK/A is ridiculous. Berkshire is basically like owning a giant mutual fund. They are and obviously always will be a much more diversified company than AMGN. Its apples and oranges. That being said, I don't think a split will do anything here, there is a widespread sell off in Biotech because of a percieved bubble. In fact, the sector is probably one of if not the strongest in the economy and will remain a cash cow long into the future as the boomers get older. All it takes is one of the 16 Phase 3 compounds that AMGN currently has in the pipeline to work for it to be massively successful. Trailing earnings multiples are BS, and sell offs like these suck, but they are a part of owning stocks unfortunately.
What is that feeling based on? Auto industries and aero are doing fine. Not sure how the price of aluminum is doing, but these dips come and go. If there is a surplus, they will offset it with a slowdown in smelting. Its the same old story. With the downstream operations taking off, the full year results should be good.
Well a reverse split of 1/10 would do it. This thing is still doomed. The transdermal technology is not new, even if the old board was garbage. They will need to sell a ton of equity to get the cash to get this thing to market.
Did people get excited over the change in directors/management? What changed? For years this stock was lingering on its death bed. Did they complete a reverse split? What happened?
A lot of selling today was on the back of a Credit Suisse analyst report that again, wasn't very bad. I think the stock will trade in a range until it is clear that revenue growth will continue at a high rate. Maybe people should focus more on GILD's other blockbuster drugs, and drugs in the pipeline, and excellent management team. There are a million things that effect stock prices every day, macro events, oil markets, currency markets, credit markets. You need to be in it to win it and there will be bad days. But if the company is undervalued and good, there will be bigger good ones.
Both Abbv and GILD have strong pipelines, cash flows from sources other than HCV. Look at the earnings per share. GILD is trading at 13x, much less than the market average over hogwash. In the end, the volume of sale at a slight discount will probably benefit both companies and they will both sell more of their HCV drugs, not to mention their existing drugs and drugs under development. Credit Suisse still had a target price of $115, and $69 for ABBV, both way above the current FV.
Yeah I noticed those names. Thats the problem, these guys create 50 accounts. Oh well what can you do, its the interweb.
Well, I did know they are involved in a lot of other business now, thats why the huge price swings seem a little crazy. It looks very undervalued to me, thank you for responding mostly there are just crazy trolls on these boards with no significant input to anything.
So, I know these are estimates which can change and what not, especially with a stock that is still pretty heavily tied to a commodity, but it seems like Alcoa is still vastly undervalued. If they achieve $1.17 in EPS for 2015, which is from Etrade, that puts their multiple at 14x. Still wayyyy below the market average, especially for a company of this size. They also have Cash flows going way up, to 2.06 or something. That would put the cash flow per share multiple at around 8x which is also very low. This stock has its ups and downs but at this point, if the earnings growth materializes, it would mean a good deal of appreciation from here. The other thing is if you look at long term aluminum charts, it really seems like prices have barely been climbing out of a multi-year trough, I guess due to overproduction by the Chinese, etc. With all signs of aluminum demand going up, I don't see how this stock didn't keep up its rally today, especially with the big rally in defense stocks etc. Its one day, but the announcement of the plant and everything probably has people selling on the news. I have my shares since 2011 or something with an average of $14. That seems pretty low considering the above. Thoughts by any non-trolls who actually have real insight into this company and industry?